Regdanvimab and CT P63 antibody cocktail - Celltrion
Alternative Names: CT-P59 and CT-P63 neutralising antibody cocktail - Celltrion; CT-P63 and CT-P59 antibody cocktail - Celltrion; CT-P63 plus Regkirona™; Neutralising antibody cocktail with CT-P59 - Celltrion; Neutralising antibody cocktail with regdanvimab - CelltrionLatest Information Update: 08 Feb 2022
At a glance
- Originator Celltrion
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 06 Feb 2022 Celltrion submits IND for a phase III trial for COVID-2019 infections
- 06 Feb 2022 Celltrion plans a global phase III trial for COVID-2019 infections (Inhalation)
- 03 Jan 2022 Celltrion plans to discuss large-scale clinical trials of regdanvimab and CT P63 antibody cocktail therapy with the regulatory agencies for COVID-2019 infections worldwide